IDEXX Laboratories Reports Strong Q4 & FY2025 Results, Provides Positive 2026 Outlook
IDXX sits 94% above its 52-week low of $356.14.
Summary
IDEXX Laboratories announced robust fourth quarter and full-year 2025 financial results, driven by strong growth in its Companion Animal Group, and issued an optimistic revenue and EPS guidance for 2026.
Key Events · Earnings and Guidance · IDXX
-
Strong Q4 2025 Performance
Achieved 14% reported revenue growth and 18% reported EPS growth for the fourth quarter of 2025, exceeding prior year results.
-
Record Instrument Placements
Reported a 76% increase in CAG Diagnostics capital instrument revenues, including over 1,900 IDEXX inVue Dx™ placements, contributing to a 12% year-over-year expansion of the global premium instrument installed base.
-
Positive 2026 Financial Outlook
Provided initial 2026 guidance projecting 7.0% - 9.0% organic revenue growth and 10% - 14% comparable EPS growth, indicating continued strong performance expectations.
Analysis · IDXX · Life Sciences
IDEXX Laboratories delivered a strong close to 2025, demonstrating robust operational execution, particularly within its Companion Animal Group. The significant growth in capital instrument revenues, driven by record placements of key diagnostic platforms like IDEXX inVue Dx™, highlights successful innovation and market penetration. The company's positive outlook for 2026, including solid revenue and EPS growth projections, suggests continued momentum and confidence in its strategic initiatives. Investors will likely view these results and guidance favorably, reinforcing the company's position as a leader in pet healthcare innovation.
At the time of this filing, IDXX was trading at $690.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $53.5B. The 52-week trading range was $356.14 to $769.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.